- Trial phase
- Phase 1
- Time to market
- VIR-5500 is in Phase 1 dose expansion. Pivotal Phase 3 trials are anticipated to begin in 2027. Even with Fast Track designation, approval is likely several years away, assuming successful development.
- Why 4/10
- VIR-5500 has no hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) within the next ~12 months. Phase 3 trials are anticipated to start in 2027, but that is a program initiation, not a binary data event. Updated Phase 1 dose expansion data may emerge but has no scheduled date. The drug is a meaningful pipeline asset for Vir but is not the company's primary near-term catalyst (the hepatitis delta ECLIPSE program has Phase 3 topline data due Q4 2026). ImpactScore of 4 reflects an early-stage drug with no imminent binary catalyst.
VIR-5500 is an early-stage but promising PSMA-targeted T-cell engager with strong Phase 1 data and a deep-pocketed partner in Astellas. The next meaningful catalyst is updated Phase 1 dose expansion data, but no date has been set. For Vir Biotechnology as a whole, the more immediate binary event is the ECLIPSE 1 Phase 3 topline readout for hepatitis delta expected in Q4 2026, which is likely to drive near-term share price action more than VIR-5500 news.
Price Chart
Executive Summary
VIR-5500 is an investigational PSMA-targeted, dual-masked T-cell engager being developed by Vir Biotechnology (Nasdaq: VIR) in collaboration with Astellas Pharma for metastatic prostate cancer. Phase 1 dose-escalation data showed encouraging efficacy (82% PSA50 response rate, 45% objective response rate at higher doses) with a favorable safety profile and no dose-limiting toxicities. The drug received FDA Fast Track designation in October 2026. A global collaboration with Astellas (up to $1.7 billion total value, $335 million upfront) provides financial and development support, with Phase 3 trials expected to begin in 2027. However, VIR-5500 remains early-stage with no near-term binary catalyst, and Vir's stock is more immediately driven by the company's hepatitis delta program (ECLIPSE Phase 3 data due Q4 2026).
How It Works
VIR-5500 is a bispecific T-cell engager (TCE), a type of immunotherapy that works like a bridge. One end of the drug grabs onto PSMA, a protein found on prostate cancer cells, while the other end grabs onto T-cells (immune cells). This forces the T-cells to attack the cancer. The drug uses a "dual-masked" PRO-XTEN technology that keeps it inactive until it reaches the tumor environment, where enzymes naturally found near tumors unmask it. This design aims to reduce side effects by limiting immune activation to the tumor site rather than throughout the body.
Trial Status
VIR-5500 is being studied in an open-label, non-randomized Phase 1 trial (NCT05997615) in patients with metastatic castration-resistant prostate cancer (mCRPC). Dose escalation in late-line mCRPC (58 patients as of January 2026) showed no dose-limiting toxicities and dose-dependent anti-tumor activity. At doses of 3,000+ ug/kg every three weeks, 82% of patients achieved a 50% or greater PSA decline (PSA50) and 45% had objective responses per RECIST criteria. Dose expansion began in April 2026, adding combination cohorts with enzalutamide, docetaxel, and darolutamide, and expanding into earlier-line mCRPC and metastatic hormone-sensitive prostate cancer (mHSPC).
The Two-Sided Case
Upcoming Catalysts
- Updated Phase 1 dose expansion data (no specific date announced)
- Initiation of Phase 3 pivotal trials anticipated in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vir Biotechnology, Inc. 8-K VIR ·Originating report